Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Sells 13,272 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 13,272 shares of Sera Prognostics stock in a transaction on Friday, January 10th. The shares were sold at an average price of $7.42, for a total transaction of $98,478.24. Following the transaction, the general counsel now owns 128,473 shares in the company, valued at $953,269.66. The trade was a 9.36 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Benjamin Jackson also recently made the following trade(s):

• On Monday, January 13th, Benjamin Jackson sold 7,912 shares of Sera Prognostics stock. The shares were sold at an average price of $6.38, for a total value of $50,478.56.
• On Monday, November 11th, Benjamin Jackson sold 4,727 shares of Sera Prognostics stock. The stock was sold at an average price of $7.32, for a total value of $34,601.64.

Sera Prognostics Stock Performance

SERA stock opened at $6.37 on Wednesday. The firm has a market cap of $215.13 million, a P/E ratio of -6.43 and a beta of 0.86. Sera Prognostics, Inc. has a 1 year low of $4.98 and a 1 year high of $12.35. The stock has a 50-day simple moving average of $7.44 and a 200-day simple moving average of $7.31.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.09 million. During the same period last year, the business earned ($0.23) earnings per share. On average, equities research analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Institutional Investors Weigh In On Sera Prognostics

A number of large investors have recently added to or reduced their stakes in the company. Quest Partners LLC lifted its holdings in Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after buying an additional 5,415 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Sera Prognostics during the second quarter worth about $68,000. SG Americas Securities LLC purchased a new stake in shares of Sera Prognostics during the third quarter worth about $78,000. Prime Capital Investment Advisors LLC acquired a new position in shares of Sera Prognostics in the third quarter worth about $104,000. Finally, Jane Street Group LLC boosted its holdings in Sera Prognostics by 24.8% in the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock valued at $111,000 after purchasing an additional 2,826 shares during the last quarter. 54.64% of the stock is owned by institutional investors and hedge funds.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.